ST. LOUIS, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will ...
PharmAla and CCrest Labs have terminated their supply agreement. CCrest was contracted in 2022 to distribute PharmAla’s MDMA to doctors under the Special Access Program. PharmAla will rely on other ...
Anne Breum, one of the employee-elected members of the Board of Directors of Novozymes A/S, part of Novonesis Group (the “Company”), has decided to step down as a board member. The first alternate, ...
Iris Bincovich, CEO of Innocan Pharma, will be presenting at 2PM ET at the Lotus Suite West on October 30th. Members of the Innocan Pharma management will also be holding one-on-one investor meetings ...
Specifically, SL dosing of ‘1104 resulted in reduced inflammatory cell infiltration, including eosinophils and neutrophils, comparable to SQ and IV routes. SL dosing of ‘1104 also led to a reduction ...
In the supplementary post-hoc analysis, treatment with solengepras 150 mg group reduced OFF time by -1.78 hours (p= 0.0045) compared to placebo and increased good ON time by +1.3 hours (p=0.04).